Zenas BioPharma (ZBIO) Research & Development (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Research & Development of $60.4 million for Q1 2026, up 73.1% year-over-year from $34.9 million in Q1 2025, and up 8.47% quarter-over-quarter from $55.7 million in Q4 2025.
Zenas BioPharma (ZBIO) Research & Development (2023 - 2026) Analysis & Trends
Zenas BioPharma's Research & Development history runs 4 years deep, the most recent figure standing at $60.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 73.1% year-over-year to $60.4 million; the TTM figure through Mar 2026 stood at $193.6 million (up 27.86% YoY), while the FY2025 annual figure was $168.1 million, up 20.79% from the prior year.
- Research & Development for Q1 2026 stood at $60.4 million, up from $55.7 million in the prior quarter.
- The five-year high for Research & Development was $60.4 million in Q1 2026, with the low at $9.4 million in Q3 2023.
- The 4-year median for Research & Development is $34.4 million (2025), against an average of $36.1 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 258.53% in 2024, then grew 2.6% in 2025.
- Zenas BioPharma's Research & Development stood at $20.4 million in 2023, then surged by 140.75% to $49.2 million in 2024, then grew by 13.35% to $55.7 million in 2025, then increased by 8.47% to $60.4 million in 2026.
- Business Quant data shows ZBIO's Research & Development at $60.4 million in Q1 2026, $55.7 million in Q4 2025, and $34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 62.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.91 Mn |
| Mar 31, 2026 | 60.44 Mn |
| Dec 31, 2025 | 55.72 Mn |
| Sep 30, 2025 | 34.40 Mn |
| Jun 30, 2025 | 43.03 Mn |
| Mar 31, 2025 | 34.92 Mn |
| Dec 31, 2024 | 49.16 Mn |
| Sep 30, 2024 | 33.53 Mn |
| Jun 30, 2024 | 33.81 Mn |
| Mar 31, 2024 | 22.65 Mn |
| Dec 31, 2023 | 20.42 Mn |
| Sep 30, 2023 | 9.35 Mn |